Tuesday, November 29, 2022 10:09:22 PM
I am perplexed about what is going on with the AVXL share price, option premiums, active buying, active selling of AVXL shares. Yesterday, as the stock price was dropping precipitously overall active buying of shares was exceeding active selling.
At the same time, December 2 call options were still trading at high premiums with only a few days to go to expiration. I sold some covered calls yesterday at good prices. I sold some more today at good prices. For example, I sold a few $17.50 December call options today at a price of $1.00 per share, 10 $17.50 strike price option contracts at a time for $1,000 with a few days to go before expiration. Another example, 10 $27 strike price option contracts at a time for $450 with a few days to go. Interestingly, when I sold these contracts today, AVXL was trading as low as $8.80 per share. I sold one December option contract at a time at first as a test, and then increased the amount of contracts to 10 at a time. All of the calls I sold were covered calls. I still have enough AVXL shares that are not covered. Selling these calls at good prices is a little tricky, but I start at bidding high and gradually cancel and replace with lower prices, but still at a good premium, until I get filled.
Either some one is going to pick a few of my shares at a cheap price, or I am going to pocket, for example, a 5.7% gain in three or four days on the $17.50 calls + a pretty good long term capital gain between my cost basis for these shares and $17.50. I have been in this stock since 2015, buying and selling shares as well as selling covered calls, puts, etc. Investing in Anavex has been a continuing education for me. If I pocket the premiums from the December 2 covered calls I have sold this week, I will be wondering why some one bought the options I sold. If any of my covered call option contracts get exercised, I will be somewhat surprised at this juncture due to the steep price decline in share price so far this week.
For the stock to reach $17.50 per share in the next few days means the price has to double, and to reach $27 per share it is approximately a tripling in share price from today.
So, why more active buyers than sellers yesterday with the big drop in share price, and why the high option premiums with only days to go to expiration? Which brings me to question some of the things I have heard about the big price drop on Monday along the lines of “the market knows such and such” and other things said about what smart, experienced investors know. I have been investing in the stock market since 1968. In the last few years, I have learned that I do not know much of anything that may happen with this stock in the next few days or at any point in the future. Frankly, the older I get the more I realize how little I know period.
At the same time, December 2 call options were still trading at high premiums with only a few days to go to expiration. I sold some covered calls yesterday at good prices. I sold some more today at good prices. For example, I sold a few $17.50 December call options today at a price of $1.00 per share, 10 $17.50 strike price option contracts at a time for $1,000 with a few days to go before expiration. Another example, 10 $27 strike price option contracts at a time for $450 with a few days to go. Interestingly, when I sold these contracts today, AVXL was trading as low as $8.80 per share. I sold one December option contract at a time at first as a test, and then increased the amount of contracts to 10 at a time. All of the calls I sold were covered calls. I still have enough AVXL shares that are not covered. Selling these calls at good prices is a little tricky, but I start at bidding high and gradually cancel and replace with lower prices, but still at a good premium, until I get filled.
Either some one is going to pick a few of my shares at a cheap price, or I am going to pocket, for example, a 5.7% gain in three or four days on the $17.50 calls + a pretty good long term capital gain between my cost basis for these shares and $17.50. I have been in this stock since 2015, buying and selling shares as well as selling covered calls, puts, etc. Investing in Anavex has been a continuing education for me. If I pocket the premiums from the December 2 covered calls I have sold this week, I will be wondering why some one bought the options I sold. If any of my covered call option contracts get exercised, I will be somewhat surprised at this juncture due to the steep price decline in share price so far this week.
For the stock to reach $17.50 per share in the next few days means the price has to double, and to reach $27 per share it is approximately a tripling in share price from today.
So, why more active buyers than sellers yesterday with the big drop in share price, and why the high option premiums with only days to go to expiration? Which brings me to question some of the things I have heard about the big price drop on Monday along the lines of “the market knows such and such” and other things said about what smart, experienced investors know. I have been investing in the stock market since 1968. In the last few years, I have learned that I do not know much of anything that may happen with this stock in the next few days or at any point in the future. Frankly, the older I get the more I realize how little I know period.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
